Crossing the Second Translational Research Valley of Death-A Lesson from Tumor Classification in the Molecular Era

Speaker: Prof. David Louis, M.D. , Harvard Medical School, Mass General Hospital

Date: Thursday, February 23, 2017

Time: 11:00 AM to 12:00 PM Note: all times are in the Eastern Time Zone

Public: Yes

Location: 1-190

Event Type:

Room Description:

Host: Arup Chakraborty, Institute for Medical Engineering and Science (IMES)

Contact:

Relevant URL:

Speaker URL: None

Speaker Photo:
None

Reminders to: seminars@csail.mit.edu

Reminder Subject: TALK: Crossing the Second Translational Research Valley of Death-A Lesson from Tumor Classification in the Molecular Era

Abstract: MOVING BASIC RESEARCH FINDINGS into the
clinical arena is said to involve crossing two “valleys of death”: one from basic science to clinical relevance and the second from clinical relevance to routine clinical practice. As we move into the era of molecular classifications of human cancer, we are learning of the challenges crossing the second valley. This talk discusses this transition in relation to the 2016 updating of the World Health Organization Classification of Tumors of the Central Nervous System.

Bio: David Louis is the Benjamin Castleman Professor of Pathology at Harvard Medical School and chair of Pathology at Massachusetts General Hospital. His clinical practice and research focuses on the molecular basis of brain tumors and the application of molecular diagnostics to brain tumor classification. Dr. Louis’ clinical neuropathology practice and research focuses on brain tumors, with an emphasis on the molecular basis of malignant gliomas and the application of molecular diagnostics to glioma classification. His laboratory was the first to demonstrate that molecular approaches could be used to subdivide malignant gliomas in a biologically relevant manner, and that molecular approaches could be used to predict the response of particular malignant gliomas to specific therapies. This work has contributed to worldwide adoption of molecular testing for the management of patients with these tumors. Dr. Louis has received a number of prestigious awards for his work, including the 2008 Zu?lch Prize of the Max Planck Society. He served on the 2000 WHO Committee on the Classification of Tumours of Nervous System; Dr. Louis also co-chaired and was the primary editor for the 2007 WHO Classification of Tumours of the Central Nervous System and the 2016 WHO Classification of Tumours of the Central Nervous System. He is currently chairing the CNS tumor committee for the International Collaboration on Cancer Reporting, and is the founder and inaugural Steering Committee chair for cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy).

Research Areas:

Impact Areas:

This event is not part of a series.

Created by Lauralyn M. Smith Email at Wednesday, January 25, 2017 at 1:44 PM.